JelikaLite is developing Cognilum, a therapeutic wearable device that utilizes near-infrared light and machine learning to provide non-invasive brain stimulation for children with Autism Spectrum Disorder (ASD). The device addresses the lack of FDA-approved treatments for core ASD symptoms, aiming to enhance communication skills and social interactions in affected children.
Funding
Funding not disclosed
Founders
Product
Problem
Autism Spectrum Disorder (ASD) lacks FDA-approved treatments for its core symptoms, such as impaired communication skills and social interaction, leading to significant challenges for affected children and their families. Existing interventions often require extensive therapy and may not adequately address the diverse needs of individuals with ASD.
Solution
JelikaLite is developing Cognilum, a therapeutic wearable device that delivers non-invasive brain stimulation using near-infrared light. The device is designed to enhance communication skills and improve social interaction in children with ASD. Cognilum incorporates sensors and a machine-learning platform to personalize treatment. The system creates a continuous feedback loop, adapting to the individual's needs to optimize therapeutic outcomes. The device is intended for home use, providing flexibility and privacy for families.
Target Audience
The primary target audience includes children diagnosed with Autism Spectrum Disorder (ASD) and their families, as well as clinicians and therapists specializing in pediatric developmental disorders.
Features
- Wearable device with integrated LEDs for near-infrared light stimulation
- Embedded sensors for real-time data collection and monitoring
- Personalized AI platform for tailored treatment protocols
- Machine learning algorithms to optimize stimulation parameters based on individual responses
- Home-based administration for convenient and flexible use
- Continuous feedback loop for adaptive therapy